Rexulti

REXULTI (brexpiprazole) Tablets 1 mg: Light yellow round film-coated tablets, debossed with "BRX" and "1" on one side.
Each film-coated tablet contains 1 mg brexpiprazole.
REXULTI (brexpiprazole) Tablets 2 mg: Light green round film-coated tablets, debossed with "BRX" and "2" on one side.
Each film-coated tablet contains 2 mg brexpiprazole.
REXULTI (brexpiprazole) Tablets 4 mg: White to off-white round film-coated tablet, debossed with "BRX" and "4" on one side.
Each film-coated tablet contains 4 mg brexpiprazole.
Excipient with known effect: 1 mg: Each film-coated tablet contains 47.4 mg lactose (as monohydrate).
2 mg: Each film-coated tablet contains 46.4 mg lactose (as monohydrate).
4 mg: Each film-coated tablet contains 44.4 mg lactose (as monohydrate).
Excipients/Inactive Ingredient: Tablet core: Lactose monohydrate, Corn starch, Microcrystalline cellulose, Low-substituted hydroxypropylcellulose, Hydroxypropylcellulose, Magnesium stearate, Purified water.
Tablet coat: Hypromellose, Talc, Titanium dioxide.
REXULTI (brexpiprazole) Tablets 1 mg: Ferric oxide (yellow).
REXULTI (brexpiprazole) Tablets 2 mg: Ferric oxide (yellow), Ferrosoferric oxide.

Pharmacotherapeutic group: Psycholeptics, other antipsychotics. ATC code: N05AX16.
Pharmacology: Pharmacodynamics: Mechanism of action: Brexpiprazole is an atypical antipsychotic agent. The pharmacology of brexpiprazole is believed to be mediated by a modulatory activity at the serotonin and dopamine systems that combines partial agonist activity at serotonergic 5-HT_1A and at dopaminergic D₂ receptors with antagonist activity at serotonergic 5-HT_2A receptors, with similar high affinities at all of these receptors (Ki: 0.1 nM to 0.5 nM). Brexpiprazole also shows antagonist activity at noradrenergic α_1B/2C receptors with affinity in the same sub-nanomolar Ki range (Ki: 0.2 nM to 0.6 nM).
Pharmacodynamic effects: Influences of genetic variation on the pharmacodynamic responses to brexpiprazole have not been investigated.
Effects on QT: The effects of brexpiprazole on the QT interval were evaluated in patients with schizophrenia or schizoaffective disorder. In the overall analysis brexpiprazole did not prolong the QT_c interval to clinically relevant extent following therapeutic and supra-therapeutic doses (4 mg/day; n=62 or 12 mg/day; n=53) and no correlation has been observed between brexpiprazole concentrations and QT_c prolongation.
Subgroup analyses from the thorough QT_c trial suggested that the QT_c prolongation was larger in female subjects than in males. In the brexpiprazole 4 mg/day group, the maximum placebo-adjusted mean change from baseline in the QT_cI interval was 5.2 ms (90% CI: 1.5, 8.9) in males (n=48) and 15.0 ms (90% CI: 7.7., 22.3) in females (n=14) at 6 hours post-dosing. In the brexpiprazole 12 mg/day group, the maximum placebo-adjusted mean change from baseline in the QT_cI interval was 2.9 ms (90% CI: -1.2, 6.9) in males (n=40) at 12 hours post-dosing and 10.4 ms (90% CI: 2.7, 18.2) in females (n=13) at 24 hours post-dosing. The smaller number of female than male subjects enrolled in the study does not allow to draw definitive conclusions.
Clinical efficacy and safety: Schizophrenia: The efficacy and safety of brexpiprazole in the treatment of adults with schizophrenia was studied in two multi-national and one regional (Japan), 6-week, randomised, double-blind, placebo-controlled, fixed-dose clinical trials (trials 1 to 3), a multi-national, 6-week, randomised, double-blind, placebo-controlled, active reference (quetiapine), flexible-dose clinical trial (trial 4), and, one multi-national, placebo-controlled, 52-week maintenance trial (trial 5). The trials included 2,690 patients with the age of 18 years to 65 years.
In trials 1, 2 and 3 brexpiprazole was titrated as described in Dosage & Administration with 1 mg for 4 days, followed by 2 mg on days 5 to 7. On day 8 the dose was increased to 4 mg for some of the treatment arms.
Short-term trials: In the three fixed-dose, short-term trials (trials 1, 2 and 3), subjects were randomised to brexpiprazole 2 mg once daily, 4 mg once daily or placebo.
Trial 4 assessed the efficacy, safety, and tolerability of brexpiprazole in a flexible dose range of 2 mg/day to 4 mg/day and 400 mg to 800 mg quetiapine extended release (XR) for assay sensitivity. In the short-term trials, the primary efficacy endpoint was defined as the mean change from baseline to week 6 in Positive and Negative Syndrome Scale (PANSS) total scores, a multi-item inventory composed of five factors to evaluate positive symptoms, negative symptoms, disorganised thoughts, uncontrolled hostility/excitement, and anxiety/depression.
The key secondary endpoint in trials 1, 2 and 4 was the Clinical Global Impression of Severity (CGI-S) of schizophrenia, a 7-point clinician's assessment of the severity of disease. The CGI-S was also assessed in trials 3 and 5 as secondary endpoint.
The effects of brexpiprazole were also evaluated across a number of pre-specified secondary endpoints; the specific aspects of symptoms of schizophrenia (PANSS Positive Subscale score, PANSS Negative Subscale score, PANSS Excited Component [PEC] score, PANSS Marder factors positive, negative, disorganised thoughts, uncontrolled hostility/excitement and anxiety/depression), and analyses of response (defined as 30% improvement in PANSS total score compared to baseline or a CGI-I score of 1 [very much improved] or 2 [much improved]).
Efficacy was demonstrated in trial 1 for both brexpiprazole 2 mg/day and 4 mg/day and replicated in trial 2 only for brexpiprazole 4 mg/day and in trial 3 only for brexpiprazole 2 mg/day.
In the flexible-dose trial 4, at week 6, subjects in the brexpiprazole treatment group had numerically greater improvements on PANSS total score than the subjects in the placebo group, although, the difference at week 6 did not reach statistical significance for the primary efficacy analysis (p=0.0560; see Table 1). In the same trial the active reference, quetiapine XR added for assay sensitivity only, separated from placebo. (See Table 1.)

Click on icon to see table/diagram/image

The primary statistical analysis was performed using an MMRM model with MAR (Missing At Random) imputation. Results of a sensitivity analysis using placebo based multiple imputation (PMI) were consistent with the primary analysis.
Results for the (key) secondary outcome parameter and additional endpoints were supportive of the primary endpoint.
In trial 1, statistically significant greater improvement on the CGI-S, the key secondary efficacy measure, at week 6 was also shown for the 2 mg/day and 4 mg/day compared to the placebo dose groups. Due to the testing hierarchy the greater improvement shown for both 2 mg/day and 4 mg/day on the CGI-S can only be considered supportive for trials 2, 3 and 4 (see Table 2).

Click on icon to see table/diagram/image

Maintenance of efficacy trial: In trial 5, a long-term trial designed to assess the maintenance of effect of brexpiprazole by assessing the delay in time to impending relapse of schizophrenia, patients with schizophrenia, who responded to treatment with brexpiprazole 1 mg/day to 4 mg/day, were stabilised over 12 weeks to 36 weeks, and then randomised in a double-blind manner to either continue treatment with the stabilisation dose of brexpiprazole (n=96) or to receive placebo (n=104) for 52 weeks or until relapse occurred.
In the primary analysis of time to impending relapse patients on brexpiprazole showed a significantly longer time to relapse compared with patients on placebo (p<0.0001). At week 52 brexpiprazole (13.5%) reduced the risk of impending relapse by 71% compared with placebo (38.5%). During the stabilisation, brexpiprazole improved clinical symptomology (as assessed by PANSS, CGI-S and CGI-I, [Analysis of Covariance - ANCOVA Last Observation Carried Forward - LOCF]) and functioning (as assessed by Global Assessment of Functioning (GAF) [ANCOVA LOCF]). These improvements were maintained during the 52-week double-blind maintenance phase in patients on brexpiprazole whereas patients randomised to placebo showed deterioration in PANSS, CGI-S and CGI-I, and GAF scores [ANCOVA LOCF]). Brexpiprazole maintained symptom control and functioning compared to placebo.
Pediatric population: The European Medicines Agency has deferred the obligation to submit the results of efficacy and safety studies with brexpiprazole in the pediatric population from 13 years to less than 18 years of age (see Dosage & Administration for information on pediatric use).
Short-term Adjunctive Treatment in Major Depressive Disorder (MDD): The efficacy of , as an adjunctive treatment to antidepressant therapy for major depressive disorder (MDD), was evaluated in four phase 3, 6-week, double-blind, placebo-controlled trials: three fixed-dose trials (331-10-228, 331-10-227, 331-13-214) and one flexible-dose trial with an active reference (331-12-282). These trials are referred to as Trials 6, 7, 8 and 9, respectively, in Table 3.
The adult patients in these trials fulfilled the DSM-IV-TR criteria for MDD, with or without symptoms of anxiety, and demonstrated an inadequate response (patient reported) to 1-3 prior antidepressant therapy(ies) in the current episode and an inadequate response during the 8-10 weeks of prospective antidepressant treatment (escitalopram, fluoxetine, paroxetine controlled-release, sertraline, duloxetine or venlafaxine extended-release) during the trials. Inadequate response to prospective antidepressant treatment in Studies 6 and 7 was initially defined as <50% improvement from baseline on the Hamilton Depression scale (HAMD-17), a HAMD-17 score >14, and a Clinical Global Impression (CGI-I) ≥3 at Week 8. To ensure that randomized patients had an inadequate response throughout the prospective antidepressant treatment phase, this definition was amended during Studies 6 and 7 to the following: <50% improvement from baseline on the HAMD-17 and a HAMD-17 score >14 at Week 8; and, CGI-I ≥3 and <50% improvement from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Weeks 2, 4, 6 and 8 (and Week 10, as applicable). This definition of inadequate response to prospective antidepressant treatment was also applied in Studies 8 and 9. With the exception of approximately 6% of patients in Studies 6 and 7, all patients who were randomized in the short-term clinical trials fulfilled the revised definition of inadequate response to prospective antidepressant treatment.
Patients remained on the same antidepressant treatment throughout the entire duration of each study. All patients randomized to in the fixed dose studies (Studies 6, 7, and 8) initiated treatment at 0.5 mg/day during Week 1. The dose was increased to 1 mg/day during Week 2 in all dose groups and, based on the assigned treatment, the dose was either maintained at 1 mg/day or increased to 3 mg/day (Study 7) or increased to 2 mg/day (Studies 6 and 8), from Week 3 onwards. Dosages were maintained at the assigned doses for the 4 remaining weeks. In the flexible dose study (Study 9), patients randomized to initiated treatment at 1 mg/day during Week 1, and the dose was increased to the target dose of 2 mg/day during Week 2. Patients remained at 2 mg/day in Study 9 unless there was a decision to increase the dose to 3 mg/day.
The primary efficacy endpoint in all studies was mean change from baseline (randomization) to Week 6 on the Montgomery Asberg Depression Rating Scale (MADRS) Total Score, a 10-item clinician-rated scale that assesses the degree of depressive symptomatology (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts). Each item is scored from 0 (normal/symptom not present) to 6 (most severe symptoms) and the range for the total score is 0 to 60.
The key secondary instrument was the Sheehan Disability Scale (SDS), a 3-item self-rated instrument used to assess three domains of functioning (work/school, social life, and family life) with each item scored from 0 (no disruption at all) to 10 (extreme disruption). (See Table 3.)

Click on icon to see table/diagram/image

Study Results: For the randomized patients, the mean duration of the current major depressive episode ranged between approximately 12 and 18 months and the majority of patients (approximately 79%-84%) reported an inadequate response to one prior antidepressant treatment, before receiving 8-10 weeks of prospective antidepressant treatment during the trials. Following 8-10 weeks of prospective antidepressant treatment, the mean MADRS Total Score at randomization ranged between 25 and 27. Mean SDS score at randomization was between 5.6 and 6.3.
In Trials 6, 8 and 9 there was greater improvement in the mean MADRS Total Score with (2 mg/day or 2-3 mg/day) + ADT compared to placebo + ADT (p<0.05). No additional benefit was demonstrated at doses greater than 2 mg/day (Table 4). In Study 9 the majority of patients treated with received 2 mg/day and the mean daily dose at endpoint was 2.2 mg/day. (See Table 4.)

Click on icon to see table/diagram/image

In Trial 6, the mean SDS score showed greater improvement with (2 mg/day) + ADT than with placebo + ADT (p<0.05).
Agitation Associated with Dementia Due to Alzheimer's Disease: The efficacy of REXULTI in the treatment of agitation associated with dementia due to Alzheimer's disease was demonstrated in two 12-week, randomized, double-blind, placebo-controlled, fixed-dose studies (Trial 10, NCT01862640 and Trial 11, NCT03548584). In these studies, patients were required to: Have a diagnosis of probable Alzheimer's disease according to NINCDS-ADRDA criteria; Have a Mini-Mental State Examination (MMSE) score of ≥5 and ≤22 and have a total score of ≥4 by the agitation/aggression item of the NPI/NPI-NH, and; Exhibit sufficient agitation behaviors at time of entry to warrant use of pharmacotherapy, after excluding other factors.
Patients in: Trial 10 were randomized to an oral dosage of either REXULTI 1 mg once a day, REXULTI 2 mg once a day, or placebo. Patients in both REXULTI groups started on 0.25 mg once daily for approximately three days, then received 0.5 mg once daily for approximately 12 days.
Subsequently, patients in the 1 mg group received 1 mg once daily for the remainder of the 12-week study, and patients in the 2 mg group received 1 mg once daily for approximately two weeks and then received 2 mg for the remainder of the study.
Trial 11 were randomized to an oral dose of either REXULTI 2 mg or 3 mg once a day (combined treatment arm) or placebo. Patients in both REXULTI groups started on 0.5 mg once daily for 7 days, then received 1 mg once daily for 7 days and then 2 mg once daily for 14 days. Subsequently, patients in the 2 mg group received 2 mg once daily for the remainder of the 12-week study, and patients in the 3 mg group received 3 mg once daily for the remainder of the study.
Trial 10 included 433 patients with a mean age of 74 years old, and a range of 51 and 90 years old; 45% were male; 96%, 3%, and 1%, were White, Black or African American, and Asian, respectively; and 16% and 83% were Latino/Hispanic and not Latino/Hispanic, respectively. Trial 11 included 345 patients with a mean age of 74 years old, and a range of 56 and 90 years old; 44% were male; 95%, 4%, and 1% were White, Black or African American, and Asian, respectively; and 31% and 69% were Latino/Hispanic and not Latino/Hispanic, respectively.
The primary efficacy endpoint in these two studies was the change from baseline in the Cohen-Mansfield Agitation Inventory total (CMAI) score at Week 12. The CMAI is a clinician rated questionnaire consisting of 29 items, which assess the frequency of manifestations of agitated behaviors in elderly patients, based on caregiver input. Three specific factors can be derived from the CMAI scale: 1) Aggressive Behavior (e.g., screaming, throwing things, cursing/verbal aggression, kicking, pushing scratching, hurting self or others); 2) Physically Non-Aggressive Behavior (e.g., repetitive mannerisms, general restlessness, pacing); and 3) Verbally Agitated Behavior (e.g., complaining, repetitive questions, constant requests for attention). Each CMAI behavior was rated on a scale of 1 (never) to 7 (very frequent agitated behaviors); the total CMAI scores range from 29 (best) to 203 (worst). A negative change indicates improvement.
In Trial 10, patients in the REXULTI 2 mg group showed improved total CMAI scores compared to patients in the placebo group at Week 12. In Trial 11, patients in the REXULTI 2 mg/3 mg group showed improved total CMAI scores compared to patients in the placebo group at Week 12.
As shown in Table 5 and in the Figure, the mean change from baseline in the total CMAI score after 12 weeks in the 2 mg/or 3 mg REXULTI group was statistically significantly superior to the placebo group. The 1 mg REXULTI group did not demonstrate significantly greater mean changes at baseline from the placebo group in the total CMAI score in this patient population. The 1 mg once day REXULTI dosage is not approved and is not recommended for the treatment of agitation associated with dementia due to Alzheimer's disease. (See Table 5 and figure.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Pharmacokinetics: Absorption: Brexpiprazole is absorbed after administration of the tablet, with peak plasma concentrations occurring within 4.0 hours after single dose administrations; the absolute oral bioavailability of the tablet formulation is 95.1%. Brexpiprazole steady-state concentrations are attained within 10 days to 12 days of dosing. Administration of a 4 mg brexpiprazole tablet with a standard high fat meal did not significantly affect the C_max or AUC of brexpiprazole. After single and multiple once daily dose administration, brexpiprazole exposure (C_max and AUC) increase in proportion to the dose administered. Based on in vivo studies, brexpiprazole is neither a substrate nor an inhibitor of efflux transporters, such as Multi Drug Resistance (MDR) 1 (P-gp) and BCRP.
Distribution: The volume of distribution of brexpiprazole following intravenous administration is high (1.56 L/kg±0.418 L/kg), indicating extravascular distribution. Brexpiprazole is highly protein bound in plasma (greater than 99%) to serum albumin and α1-acid glycoprotein, and its protein binding is not affected by renal or hepatic impairment. Based on results of in vitro studies brexpiprazole protein binding is not affected by warfarin, diazepam, and digitoxin.
Biotransformation: Based on in vitro metabolism studies using recombinant human cytochrome P450, the metabolism of brexpiprazole was shown to be mainly mediated by CYP3A4 and CYP2D6 leading to formation of oxidative metabolites. Based on in vitro data brexpiprazole showed little to no inhibition of other CYP450 isozymes. In vivo, the metabolism of brexpiprazole is mainly mediated by CYP3A4 and CYP2D6 leading to formation of oxidative metabolites with only one metabolite, DM-3411, present in plasma with more than 10% of plasma exposure.
At steady-state, DM-3411 represents 23.1% to 47.7% of brexpiprazole exposure (AUC) in plasma. It should be noted that in vivo preclinical studies have shown that at clinically relevant plasma exposures of brexpiprazole, DM-3411 brain exposures were below the detection limit. Thus, DM-3411 is considered not to contribute to the therapeutic effects of brexpiprazole.
Elimination: Following a single oral dose of [¹⁴C]-labelled brexpiprazole, approximately 24.6% and 46% of the administered radioactivity was recovered in the urine and faeces, respectively. Less than 1% of unchanged brexpiprazole was excreted in the urine and approximately 14% of the oral dose was recovered unchanged in the faeces. Apparent oral clearance of brexpiprazole tablet after once daily administration is 19.8 (±11.4) mL/h/kg. After multiple once daily administration of brexpiprazole, the terminal elimination half-life of brexpiprazole and its major metabolite, DM-3411, is 91.4 hours and 85.7 hours, respectively.
Linearity/non-linearity: The pharmacokinetic of brexpiprazole is dose proportional and time-invariant after single-dose (0.2 mg to 8 mg) and multiple-dose (0.5 mg to 4 mg) using once-daily administration.
Pharmacokinetics in special populations: Age: After single dose administration of brexpiprazole (2 mg), elderly subjects (older than 65 years) exhibited similar brexpiprazole systemic exposure (C_max and AUC) in comparison with the adult subjects (18 years to 45 years old; see Dosage & Administration and Precautions).
Gender: Population PK evaluation identified gender as statistically significant covariate. The exposure (AUC) of brexpiprazole in women was estimated to be 25% higher than in men (see Adverse Reactions).
Race: Although no specific pharmacokinetic study was conducted, population pharmacokinetic evaluation revealed no evidence of clinically significant race-related differences in the pharmacokinetics of brexpiprazole.
CYP2D6 genotype: Population pharmacokinetic evaluation shows that CYP2D6 poor metabolisers have 47% higher exposure to brexpiprazole compared to extensive metabolisers (see Dosage & Administration).
Smoking: Based on studies utilising human liver enzymes in vitro, brexpiprazole is not a substrate for CYP1A2; smoking should, therefore, not have an effect on the pharmacokinetics of brexpiprazole.
Renal impairment: In subjects (n=10) with severe renal impairment (CL_cr <30 mL/min), AUC of oral brexpiprazole (3 mg single dose) compared to matched healthy subjects was increased by 68% while its C_max was not changed. For patients with moderate to severe renal impairment (creatinine clearance CL_cr <60 mL/minute), the maximum recommended dose is reduced to 3 mg once daily for patients with schizophrenia and 2 mg once daily for patients with MDD (see Dosage & Administration).
Hepatic impairment: In subjects (n=22) with varying degrees of hepatic impairment (Child-Pugh Classes A, B, and C), the AUC of oral brexpiprazole (2 mg single dose), compared to matched healthy subjects, increased 24% in mild hepatic impairment, increased 60% in moderate hepatic impairment, and did not change in severe hepatic impairment. For patients with moderate to severe hepatic impairment (Child-Pugh Classes B and C), the maximum recommended dose is reduced to 3 mg once daily for patients with schizophrenia and 2 mg once daily for patients with MDD (see Dosage & Administration).
Pediatric population: A multiple dose PK study (0.5, 1, 2, 3 or 4 mg/day) has been conducted in 43 pediatric patients aged 13 years to 17 years old. Population PK analysis indicated systemic exposure (C_max and AUC) of brexpiprazole in pediatric patients (13 to 17 years of age) was comparable to that in adult patients across the dose range from 0.5 to 4 mg.
Toxicology: Preclinical safety data: Effects observed in repeated-dose toxicity studies in rats and monkeys were mainly related to the exaggerated pharmacological activity of brexpiprazole. No safety margins based on AUC_{0-24 h} at the Maximum Recommended Human Dose (MRHD) of 4 mg/day could be derived in both female and male rats and monkey.
Cardiovascular toxicity: Following oral administration, brexpiprazole decreased blood pressure and prolonged QT interval in safety pharmacology study in conscious male dog, in repeated-dose toxicity studies in male and female monkeys and in juvenile toxicity study in male and female dogs. The effect of brexpiprazole on blood pressure reduction is attributed to the expected blockade of α1-adrenoceptors in peripheral blood vessels.
Genotoxicity, carcinogenicity: Brexpiprazole did not show any genotoxic potential in both in vitro and in vivo studies using clinically relevant exposures. Brexpiprazole administered orally did not increase in the incidence of tumours in 2-year carcinogenicity study in both male and female rats and in male mice at exposures up to 4.4-fold and 3.1-fold the MRHD. In female mice, an increased incidence of mammary gland adenocarcinoma and adeno-squamous carcinoma, and pars distalis adenoma of the pituitary gland, was observed at similar or even lower clinically relevant exposures: these prolactin-mediated endocrine tumours were also observed in rodents with other antipsychotics and their clinical relevance is unknown.
Reproductive toxicity: Following oral administration, brexpiprazole did not affect male fertility in rats but prolonged diestrus and decreased fertility in female rats at similar or even lower exposure levels than those clinically achieved at MRHD. Significant increased pre-implantation losses were observed at 4.1-fold the clinical exposure at MRHD. In embryo-foetal developmental toxicity studies, brexpiprazole was not teratogen in orally treated rats up to exposure levels (based on data in non-pregnant rats) clinically achieved at MRHD. In rabbit, vertebral malformations were seen in 3 foetuses from 2 litters at 21 maternally toxic brexpiprazole oral doses corresponding to exposure approximately 16.5-fold the clinical exposure at MRHD.
Delayed growth, physical development and impaired viability of the offspring were observed at maternally toxic brexpiprazole doses in a pre-/post-natal developmental toxicity study in orally administered rats.
Following oral administration in pregnant rats, foetus and milk transfer of brexpiprazole was demonstrated at concentrations that were generally comparable to levels seen in maternal blood.
Environmental risk assessment (ERA): Brexpiprazole is very persistent and very bioaccumulative but not toxic, to the environment: possible enrichment of brexpiprazole in terrestrial food chains might pose a concern (see Cautions for Usage).

REXULTI is indicated for: Adjunctive treatment of major depressive disorder (MDD) in adult.
Treatment of schizophrenia in adult and pediatric patients ages 13 years and older.
Treatment of agitation associated with dementia due to Alzheimer's disease.
Limitations of Use: REXULTI is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease.

Posology: Schizophrenia (Adults and Pediatric Patients 13 to 17 Years): Adults: The recommended starting dose for brexpiprazole is 1 mg once daily on days 1 to 4.
The recommended target dose range is 2 mg to 4 mg once daily.
Based on the patient's clinical response and tolerability the brexpiprazole dose can be titrated to 2 mg once daily on day 5 through day 7 and then to 4 mg on day 8.
The maximum recommended daily dose is 4 mg.
Pediatric Patients 13 to 17 Years: The recommended starting dosage for brexpiprazole is 0.5 mg once daily on days 1 to 4.
The recommended target dose range is 2 mg to 4 mg once daily.
Based on the patient's clinical response and tolerability the brexpiprazole dose can be titrated to 1 mg once daily on day 5 through day 7, then to 2 mg on day 8.
Weekly dose increases can be made in 1 mg increments.
The maximum recommended daily dosage is 4 mg.
Switching from other antipsychotics to brexpiprazole: When switching from other antipsychotics to brexpiprazole gradual cross-titration should be considered, with gradual discontinuation of the previous treatment while brexpiprazole treatment is initiated.
Switching to other antipsychotics from brexpiprazole: When switching to other antipsychotics from brexpiprazole, no gradual cross-titration is needed, the new antipsychotic should be initiated in its lowest dose while brexpiprazole is discontinued. It should be considered that plasma concentration of brexpiprazole will decline gradually and will be completely washed out in 1 to 2 weeks.
Major Depressive Disorder (Adults): The recommended starting dose for brexpiprazole as adjunctive treatment is 0.5 mg or 1 mg once daily.
Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient's clinical response and tolerability.
The maximum recommended daily dosage is 3 mg.
Periodically reassess to determine the continued need and appropriate dosage for treatment.
Agitation Associated with Dementia Due to Alzheimer's Disease: The recommended starting REXULTI dosage for the treatment of agitation associated with dementia due to Alzheimer's disease is 0.5 mg taken once daily on Days 1 to 7. Increase the dosage on Days 8 through 14 to 1 mg once daily, and on Day 15 to 2 mg once daily. The recommended target dose is 2 mg once daily. The dosage can be increased to the maximum recommended daily dosage of 3 mg once daily after at least 14 days, based on clinical response and tolerability.
Special populations: Elderly: The safety and efficacy of brexpiprazole in the treatment of schizophrenia in patients aged 65 years and older have not been established (see Precautions and Pharmacology: Pharmacokinetics under Actions). It is not possible to advise on a minimum effective/safe dose in this population.
The total number of REXULTI-treated patients 65 years of age and older in the clinical studies for agitation associated with dementia due to Alzheimer's disease was 448 (86%) including 170 (33%) patients 65 to 74 years of age, 228 (44%) patients 75 to 84 years of age, and 50 (10%) patients 85 years of age and older (see Pharmacology: Pharmacokinetics under Actions).
In clinical studies of REXULTI for the treatment of agitation associated with dementia due to Alzheimer's disease did not include sufficient numbers of younger adult patients to determine if patients 65 years of age and older respond differently than younger adult patients.
Renal impairment: The maximum recommended dose in patients with moderate to severe impaired renal function is reduced to 3 mg once daily for patients with schizophrenia, and 2 mg once daily for patients with MDD or agitation associated with dementia due to Alzheimer's disease (see Pharmacology: Pharmacokinetics under Actions).
Hepatic impairment: The maximum recommended dose in patients with moderate to severe hepatic impairment (Child Pugh score ≥7) is reduced to 3 mg once daily for patients with schizophrenia, and 2 mg once daily for patients with MDD or agitation associated with dementia due to Alzheimer's disease (see Pharmacology: Pharmacokinetics under Actions).
CYP2D6 poor metabolisers: Dosing modifications to half the recommended doses is required for patients with known CYP2D6 poor metaboliser status. Further dosing modifications to a quarter of the recommended dose is required for known CYP2D6 poor metabolisers while taking strong or moderate CYP3A4 inhibitors (see Interactions and Pharmacology: Pharmacokinetics under Actions).
Dose adjustments due to interactions: Dose adjustments should be made in patients taking concomitant strong CYP3A4 inhibitors/inducers or strong CYP2D6 inhibitors. If the CYP3A4 inhibitor/inducers or CYP2D6 inhibitor is withdrawn, the dose may need to be returned to the original dose (see Interactions). In case of adverse reactions despite dose adjustments of REXULTI, the necessity of concomitant use of REXULTI and CYP2D6 or CYP3A4 inhibitor should be reassessed. (See Table 6.)

Click on icon to see table/diagram/image

Patients taking strong CYP3A4 inducers: If brexpiprazole is used concomitantly with strong CYP3A4 inducers (e.g. rifampicin), in a patient stabilised on brexpiprazole it is necessary to titrate the daily dose of brexpiprazole stepwise up to double the recommended dose over the course of 1 to 2 weeks. Thereafter, if according to clinical response, further dose adjustments are required, the dose may be increased up to a maximum of three times the recommended daily dose. Daily dose must not exceed 12 mg when brexpiprazole is used concomitantly with strong CYP3A4 inducers. Twice daily divided dosing of brexpiprazole is preferable as once daily dosing results in high peak to trough fluctuation (see Interactions).
CYP3A4 inducers exert their effect in a time-dependent manner, and may take at least 2 weeks to reach maximal effect after introduction. Conversely, on discontinuation, CYP3A4 induction may take at least 2 weeks to decline.
Pediatric population: Schizophrenia: Safety and effectiveness of REXULTI for treatment of schizophrenia have been established in pediatric patients 13 years of age and older. Use of REXULTI in this population is supported by evidence from adequate and well-controlled studies in adults with schizophrenia, pharmacokinetic data from adults and pediatric patients, and safety data in pediatric patients 13 to 17 years of age.
Major Depressive Disorder and agitation associated with dementia due to Alzheimer's disease: The safety and efficacy of brexpiprazole in children and adolescents aged less than 18 years have not been established. No data are available.
Method of administration: Oral use.
The film-coated tablets can be taken with or without food.

Gastric lavage and treatment with an emetic may be useful immediately after overdose. An electrocardiogram should be obtained in case of overdose and if QT interval prolongation is present, cardiac monitoring should be instituted.
Otherwise, management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring should continue until the patient recovers.
Oral activated charcoal and sorbitol (50 g/240 mL), administered one hour after ingesting 2 mg oral dose of brexpiprazole, decreased brexpiprazole C_max and AUC by approximately 5% to 23% and 31% to 39% respectively; however, there is insufficient information available on the therapeutic potential of activated charcoal in treating an overdose with brexpiprazole.
Although there is no information on the effect of haemodialysis in treating an overdose with brexpiprazole, haemodialysis is unlikely to be useful in overdose management since brexpiprazole is highly bound to plasma proteins.

Hypersensitivity to the active substance or to any of the excipients listed in Description.

During antipsychotic treatment, improvement in the patient's clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period.
Suicidal ideation and behaviour: The occurrence of suicidal behaviour is inherent in psychotic illnesses and mood disorders and in some cases has been reported early after initiation or switch of antipsychotic treatment, including treatment with brexpiprazole (see Adverse Reactions). Close supervision of high-risk patients should accompany antipsychotic treatment.
Cardiovascular disorders: Brexpiprazole has not been evaluated in patients with a history of myocardial infarction/ischaemic heart disease or clinically significant cardiovascular disease since such patients were excluded from clinical trials.
Brexpiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension (including accelerated or malignant).
QT prolongation: QT prolongation can develop in patients treated with antipsychotics. In clinical trials, only a few, non-serious, QT prolongations have been reported with brexpiprazole. Caution should be exercised when brexpiprazole is prescribed in patients with known cardiovascular disease, family history of QT prolongation, electrolyte imbalance or in concomitant use with other medicinal products thought to prolong the QT interval (see Adverse Reactions and Pharmacology: Pharmacodynamics under Actions).
Venous thromboembolism: Cases of venous thromboembolism (VTE) have been reported with antipsychotics. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with brexpiprazole and preventive measures undertaken.
Orthostatic hypotension and syncope: Adverse reactions related to orthostatic hypotension can include dizziness, light-headedness and tachycardia. Generally, these risks are greatest at the beginning of treatment with antipsychotics and during dose escalation. Patients at increased risk of these adverse reactions (e.g. elderly) or at 5 increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medicinal products, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease, as well as patients who are antipsychotic-naive. In such patients, a lower starting dose and slower titration should be considered, and orthostatic vital signs should be monitored (see Dosage & Administration).
Neuroleptic Malignant Syndrome (NMS): A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic treatment, including brexpiprazole (see Adverse Reactions). Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include increased creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS brexpiprazole must be discontinued immediately.
Extrapyramidal symptoms (EPS): Extrapyramidal symptoms (including acute dystonia) are known class effects for antipsychotics. Brexpiprazole should be used with caution in patients with a known history of EPS.
Tardive dyskinesia: A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotics. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. If signs and symptoms of tardive dyskinesia appear in a patient on brexpiprazole, dose reduction or discontinuation should be considered. These symptoms can temporally deteriorate or can even arise after discontinuation of treatment.
Cerebrovascular adverse reactions: In placebo-controlled trials with some antipsychotics in elderly patients with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities, compared to placebo-treated subjects.
Hyperglycaemia and diabetes mellitus: Hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Risk factors that may predispose patients to severe complications include obesity and family history of diabetes.
Patients treated with any antipsychotics, including brexpiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness). Fasting plasma glucose should be assessed before or soon after the initiation of the antipsychotic treatment. During long term treatment the plasma glucose levels should be monitored regularly for worsening of glucose control.
Patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
Weight gain and dyslipidaemia: Antipsychotics including brexpiprazole have been associated with metabolic changes, including weight gain and dyslipidaemia. An increased frequency of weight gain has been observed with increased duration of brexpiprazole treatment (see Adverse Reactions). At the beginning of treatment the lipid profile should be assessed. Clinical monitoring of weight and lipid profile is recommended at baseline and during treatment.
Seizures: As with other antipsychotics, brexpiprazole should be used with caution in patients who have a history of seizure disorder or other conditions that potentially lower the seizure threshold. Seizures have been reported during use of brexpiprazole (see Adverse Reactions).
Body temperature regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotics. Appropriate care is advised when prescribing brexpiprazole for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medicinal products with anticholinergic activity, or being subject to dehydration.
Dysphagia: Oesophageal dysmotility and aspiration have been associated with antipsychotic use. Brexpiprazole should be used cautiously in patients at risk for aspiration pneumonia.
Impulse-control disorders: Impulse-control disorders including gambling disorder have been reported in patients treated with brexpiprazole. Patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking brexpiprazole. Other urges, reported, include: compulsive sexual behaviours, compulsive shopping, binge eating, and other impulsive and compulsive behaviours. Patients with a prior history of impulse-control disorders may be at increased risk and should be monitored carefully. Because patients may not recognise these behaviours as abnormal, it is important for prescribers to ask patients or their caregivers specifically about the development of new or increased impulse-control disorders or other compulsive behaviours while being treated with brexpiprazole. It should be noted that impulse-control symptoms can be associated with the underlying disorder; however, in some cases, urges were reported to have stopped when the dose was reduced or the medication was discontinued. Compulsive behaviours may result in harm to the patient and others if not recognised. Consider dose reduction or stopping the medication if a patient develops such urges while taking brexpiprazole (see Adverse Reactions).
Leukopenia, neutropenia and agranulocytosis: Leukopenia, neutropenia and agranulocytosis (including fatal cases) have been reported during treatment with antipsychotics. Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with a pre-existing low WBC or a history of drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and brexpiprazole should be discontinued at the first sign of decline in WBC, in the absence of other causative factors. Patients with neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1,000/mm³) should discontinue brexpiprazole and have their WBC followed until recovery.
Prolactin: Brexpiprazole can elevate prolactin levels. Elevations associated with brexpiprazole treatment are generally mild and may decline during administration, however, in some infrequent cases the effect may persist during administration (see Adverse Reactions).
Lactose: REXULTI film-coated tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Effects on ability to drive and use machines: Brexpiprazole has minor to moderate influence on the ability to drive and use machines due to potential nervous system effects, such as sedation and dizziness that are common adverse drug reactions (see Adverse Reactions). Patients should be cautioned about operating hazardous machinery including motor vehicles until they are certain that brexpiprazole therapy does not affect them adversely.
Use in the Elderly: Elderly patients with dementia-related psychosis: Brexpiprazole has not been studied in elderly patients with dementia and is not recommended to treat elderly patients with dementia due to increased risk of overall mortality.
Brexpiprazole is not approved for the treatment of dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease.

Pregnancy: There are no or limited amount of data from the use of brexpiprazole in pregnant women. Studies in animals have shown reproductive toxicity (see Pharmacology: Pharmacodynamics: Toxicology: Preclinical safety data under Actions). Brexpiprazole is not recommended during pregnancy and in women of childbearing potential not using contraception.
Neonates exposed to antipsychotics, including brexpiprazole, during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder. Consequently, new-borns should be monitored carefully.
Breast-feeding: It is unknown whether brexpiprazole/metabolites are excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of brexpiprazole/metabolites in milk of rats (see Pharmacology: Toxicology: Preclinical safety data under Actions). A risk to the new-borns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from brexpiprazole therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Fertility: The effect of brexpiprazole on human fertility has not been evaluated. Studies in animals have shown decreased female fertility (see Pharmacology: Toxicology: Preclinical safety data under Actions).

Clinical Trial Data For Schizophrenia: Summary of the safety profile: The most frequently observed adverse drug reactions (ADRs) were akathisia (5.6%) and weight gain (3.9%).
Tabulated list of adverse reactions: The incidences of the ADRs associated with brexpiprazole therapy are tabulated as follows. The table is based on adverse reactions reported in short-term placebo-controlled phase 2 and 3 clinical trials with relevant therapeutic doses (2 mg to 4 mg).
All ADRs are listed by system organ class (SOC) and frequency: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. (See Table 7.)

Click on icon to see table/diagram/image

Description of selected adverse reactions: Extrapyramidal Symptoms (EPS): Akathisia was the most frequently reported EPS related ADR in the brexpiprazole 2 mg/day to 4 mg/day group (5.6%) compared to 4.5% in placebo, followed by tremor (2.7%) compared to 1.2% in placebo. The incidences of other EPS-related ADRs reported in short-term, controlled trials are dyskinesia (0.4%), extrapyramidal disorder (1.8%) and Parkinsonism (0.4%).
Akathisia: From fixed-dose trials there appears to be a dose-response relationship for akathisia in patients treated with brexpiprazole, with an increasing frequency with higher doses. The incidence of akathisia in the brexpiprazole 1 mg/day, 2 mg/day, and 4 mg/day groups was 3.0%, 4.6%, and 6.5%, respectively, compared with 5.2% of subjects in the placebo group.
The incidence of akathisia in the short-term, controlled trials (5.4%) was similar to the incidence in the long-term, open-label trials (5.7%).
Suicidality: In short-term, controlled trials, Treatment Emergent Adverse Events (TEAEs) related to suicidality were reported for 8 subjects (0.5%, 2 serious events, 1 leading to discontinuation) in the all brexpiprazole treatment group and 3 subjects (0.4%, none serious) in the placebo group. In long-term, open-label trials, TEAEs related to suicidality were reported for 23 subjects (1.6%). Overall in the brexpiprazole clinical development program for schizophrenia, one death due to suicide, considered not drug related by the investigator, occurred. Spontaneous cases reporting completed suicide and suicide attempt have been reported in the post-marketing setting.
QT prolongation: In the short-term controlled trials with brexpiprazole, 3 TEAEs related to QT prolongation were reported in the 2 mg to 4 mg group (0.3%), compared with 3 TEAEs (0.5%) reported for subjects on placebo. The incidence of TEAEs in long-term trials was similar to that of the short-term trials. The effects of brexpiprazole at therapeutic (4 mg) and supra-therapeutic (12 mg) doses on QT interval were evaluated in subjects with schizophrenia or schizoaffective disorder in a randomised, double-blind, placebo- and positive-controlled (moxifloxacin), parallel-arm trial. Subgroup analyses from this trial suggested that the QTc prolongation was larger in female subjects than in males (see Pharmacology: Pharmacodynamics under Actions).
Weight gain: Adults: In short-term, controlled trials, the percentage of subjects with clinically significant weight gain (increase of ≥7% from baseline in body weight) was 9.1% in the brexpiprazole 2 mg/day to 4 mg/day group, compared with 3.8% in the placebo group.
In the long-term, open-label trial, the percentage of subjects with clinically significant weight gain (increase of ≥7% in body weight) at any visit was 20.7% and 0.4% of the subjects discontinued due to weight gain. In subjects who had a weight gain ≥7% from baseline, weight increased over time, with mean weight gain up to 10.2 kg at week 52. The mean change in body weight overall for the brexpiprazole group in the long term, open label trial was 2.1 kg at week 52.
Pediatric Patients (13 to 17 years of age): In the long-term, open label study in pediatric patients with schizophrenia, 0.5% of patients discontinued due to weight increase. The mean increase in weight from the open-label study baseline to last visit was 3.8 kg. To adjust for normal growth, z-scores were derived (measured in standard deviations [SD]), which normalize for natural growth of children and adolescents by comparisons to age- and gender-matched population standards. A z score change <0.5 SD is considered not clinically significant. In this trial, the mean change in z-score from open-label baseline to last visit was 0.10 SD for body weight, while 20% of patients had an increase in age-and-gender-adjusted body weight z-score of at least 0.5 SD from baseline. When treating pediatric, weight gain should be monitored and assessed against that expected for normal growth.
Hyperglycaemia: In the long-term, open-label study in pediatric patients with schizophrenia, 2.7% of pediatric patients with normal baseline fasting glucose experienced a shift from normal (<100 mg/dL) to high (≥126 mg/dL) while taking REXULTI.
Dyslipidemia: In the long-term, open-label study in pediatric patients with schizophrenia, shifts in baseline fasting total cholesterol from normal to high (<170 to ≥200 mg/dL) were reported in 7% of patients taking REXULTI, and shifts in baseline HDL cholesterol from normal to low (≥40 to <40 mg/dL) were reported in 12.9% of patients taking REXULTI. Of patients with normal baseline triglycerides, 8.5% experienced shifts from normal to high (<150 to ≥200 mg/dL).
Prolactin: The incidence of blood prolactin increased was 0.9% in 2 mg to 4 mg brexpiprazole group compared to that of 0.5% in placebo in short-term, controlled trials. Higher frequencies of prolactin increased (1.5% versus 0.60%) were observed in females compared to males in short-term trials. In addition, the frequencies of prolactin elevations >1 × ULN in the 2 mg to 4 mg brexpiprazole group was 13.7% in females versus 6.4% in placebo and 11.1% in males versus 10.3% in placebo group.
Neuroleptic malignant syndrome: A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with brexpiprazole (see Precautions).
Nausea: For nausea, the incidence in the 2 mg to 4 mg brexpiprazole group was 2.3% overall in short-term controlled trials, compared to 2.0% in placebo; for vomiting, these incidences were 1.0% in the brexpiprazole-treated group compared to 1.2% in placebo group.
In terms of gender differences, there were higher observed frequencies of nausea (4.8% versus 2.8%) and vomiting (4.6% versus 1.4%) in females compared to males among brexpiprazole-treated subjects in short-term trials, in subjects receiving placebo: the frequency for nausea was 2.8% for males versus 3.2% for females and for vomiting the frequency was 3.0% for males versus 2.6% for females (see Pharmacology: Pharmacokinetics under Actions).
Pediatric Patients (13 to 17 years of age): In an on-going, 2 year, open-label study in pediatric patients 13 to 17 years of age with schizophrenia, in which safety was assessed in 194 patients of which 140 received REXULTI for at least 6 months. Adverse reactions reported in clinical studies for this age group were generally similar to those observed in adult patients.
Clinical Trial Data For Major Depressive Disorder: The table as follows shows the incidence of adverse reactions that occurred in at least 2% of patients treated with 1-3 mg brexpiprazole+ADT treated group and observed more frequently than placebo. (See Table 8.)

Click on icon to see table/diagram/image

Adverse reactions that occurred <2% and the difference between brexpiprazole and placebo ≥0.5% in the short-term; placebo-controlled MDD adjunctive therapy clinical trials included palpitations, blepharospasm, toothache, salivary hypersecretion, urinary tract infection, blood prolactin increased, blood cortisol decreased, aspartate aminotransferase increased, muscle spasms, tension, night sweats and hypertension.
Selected Adverse Reactions: Extrapyramidal Symptoms: In the three 6-week, placebo-controlled, fixed-dose and one 6-week, placebo-controlled, flexible-dose MDD studies for brexpiprazole-treated patients, the incidence of reported EPS-related events, excluding akathisia events, was 5% versus 3% for placebo-treated patients. The incidence of akathisia events for brexpiprazole-treated patients was 8% versus 3% for placebo-treated patients.
Clinical Chemistry Findings: Weight Gain: In the long-term, open-label MDD studies, the mean change in body weight from baseline to last visit was 2.6 kg (N=2232). The proportion of patients with a ≥7% increase in body weight at last visit was 22.12% (494/2232) and with a ≥7% decrease in body weight was 3.2% (72/2232). At 52 weeks, the proportion of patients with a ≥7% increase in body weight was 28.2% (286/1013) and with a ≥7% decrease in body weight was 3.7% (37/1013). Weight gain led to discontinuation of study medication in 3.8% (84/2240) of patients.
Fasting Glucose: In the long-term, open-label MDD studies, 5.22% of patients with normal baseline fasting glucose experienced a shift from normal to high while taking brexpiprazole, 24.35% of subjects with borderline fasting glucose experienced shifts from borderline to high. Combined, 9.06% of patients with normal or borderline fasting glucose experienced shifts to high fasting glucose during the long-term MDD studies. The mean change from baseline for fasting glucose to last visit in the long-term, open label trials was 3.53 [2.00] mg/dL.
Fasting Lipids: In the long-term open-label studies, shifts in baseline fasting cholesterol from normal to high were reported in 8.65% (total cholesterol), 3.20% (LDL cholesterol), and shifts in baseline from normal to low were reported in 13.30% (HDL cholesterol) of patients taking brexpiprazole. Of patients with normal baseline triglycerides, 17.26% experienced shifts to high, and 0.22% experienced shifts to very high triglycerides. Combined, 0.61% of patients with normal or borderline fasting triglycerides experienced shifts to very high fasting triglycerides during the long-term MDD studies. The mean changes from baseline for fasting HDL cholesterol, fasting LDL cholesterol, fasting cholesterol and fasting triglycerides to last visit in the long-term, open label trials were -2.13 [-2.00] mg/dL, 1.36 [1.00] mg/dL, 0.05 [0.00] mg/dL and 11.46 [8.00] mg/dL, respectively.
Clinical Trial Data For Agitation Associated With Dementia Due to Alzheimer's Disease: Adverse reactions associated with REXULTI (incidence ≥2% and greater than placebo) during the 12-week fixed-dose clinical studies in geriatric patients for treatment of agitation associated with dementia due to Alzheimer's disease are shown in the Table as follows. (See Table 9.)

Click on icon to see table/diagram/image

Extrapyramidal Symptoms: The incidence of reported EPS-related adverse reactions, excluding akathisia, was 3% for REXULTI treated patients versus 2% for placebo-treated patients. The incidence of akathisia events for REXULTI-treated patients was 1% versus 0% for placebo-treated patients.
In the 12-week placebo-controlled, fixed-dose studies in agitation associated with dementia due to Alzheimer's disease, data was objectively collected on the Simpson-Angus Rating Scale (SAS) for EPS, the Barnes Akathisia Rating Scale (BARS) for akathisia and the Abnormal Involuntary Movement Scale (AIMS) for dyskinesia. The mean change from baseline at last visit for REXULTI-treated patients for the SAS, BARS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in REXULTI-treated patients versus placebo for the SAS (6% versus 2%).
Clinical Chemistry Findings: Weight gain: In the 12-week placebo-controlled, fixed-dose clinical studies in patients (51 to 90 years of age) with agitation associated with dementia due to Alzheimer's disease, the proportion of the patients with a ≥7% increase in body weight (kg) at any visit were 2% in REXULTI compared to 0% in placebo group. In patients who were previously treated with REXULTI for 12 weeks and who continued into a 12-week, active-treatment extension study, there was no mean change in weight (kg) from baseline to last visit in association with REXULTI. In this extension study, 4% of patients demonstrated ≥7% increase in body weight, and 5% demonstrated a ≥7% decrease in body weight from baseline to last visit.
Fasting Glucose: In the 12-week placebo-controlled, fixed-dose studies in patients (51 to 90 years of age) with agitation associated with dementia due to Alzheimer's disease, the proportions of patients with shifts in fasting glucose from normal (<100 mg/dL) to high (≥126 mg/dL) or impaired (≥100 and <126 mg/dL) to high were similar in patients treated with REXULTI (14%) and patients treated with placebo (16%).
Of the patients who were previously treated with REXULTI for 12-weeks and continued into a 12-week, active-treatment extension study, 15% of patients with normal baseline fasting glucose experienced a shift from normal (<100 mg/dL) to high (≥126 mg/dL) fasting glucose while taking REXULTI; 30% of patients with impaired fasting glucose experienced shifts from impaired fasting glucose (≥100 and <126 mg/dL) to high fasting glucose. Combined, 20% of patients with normal or impaired fasting glucose experienced shifts to high fasting glucose.
Fasting Lipids: In the 12-week placebo-controlled, fixed-dose clinical studies in patients (55 to 90 years of age) with agitation associated with dementia due to Alzheimer's disease, changes in total cholesterol, LDL cholesterol, and HDL cholesterol were similar in REXULTI- and placebo-treated patients. The Table as follows shows the proportions of patients with changes in fasting triglycerides in REXULTI- and placebo-treated patients. (See Table 10.)

Click on icon to see table/diagram/image

Of the patients who were previously treated with REXULTI for 12 weeks and continued into a 12-week, active-treatment extension study, 9% of patients taking REXULTI showed shifts in baseline fasting total cholesterol from normal (<200 mg/dL) to high (≥240 mg/dL), and 16% of patients taking REXULTI showed shifts in baseline HDL cholesterol from normal to low (≥40 to <40 mg/dL). Of the patients with normal baseline triglycerides, 18% experienced shifts from normal (<150 mg/dL) to high (200 to <500 mg/dL).

Brexpiprazole is predominantly metabolised by CYP3A4 and CYP2D6.
Potential for other medicinal products to affect brexpiprazole: CYP3A4 inhibitors: Co-administration of ketoconazole (200 mg twice daily for 7 days), a potent inhibitor of CYP3A4, with a 2 mg single oral dose of brexpiprazole increased the AUC of brexpiprazole by 97% and no change in C_max. Based on results of interaction studies, dose adjustment of brexpiprazole to half the dose is recommended when administered concomitantly with strong CYP3A4 inhibitors (itraconazole, ketoconazole, ritonavir, and clarithromycin).
CYP3A4 inducers: Co-administration of rifampicin (600 mg twice daily for 12 days), a potent CYP3A4 inducer, with a single 4 mg oral dose of brexpiprazole resulted in an approximate 31% and 73% decrease in brexpiprazole C_max and AUC, respectively. If brexpiprazole is used concomitantly with strong CYP3A4 inducers (e.g. rifampicin), the total daily dose requirement of brexpiprazole is increased by approximately a factor of three times the recommended daily dose (see Dosage & Administration). Once daily dosing while CYP3A4 inducers are administered results in high peak to trough fluctuation, hence twice daily divided dosing is preferable.
CYP2D6 inhibitors: Co-administration of a 2 mg single oral dose of brexpiprazole with quinidine (324 mg/day for 7 days), a potent inhibitor of CYP2D6, increased the AUC of brexpiprazole by 94% and no change in C_max. Based on results of interaction studies, dose adjustment of brexpiprazole to half the dose is recommended when administered concomitantly with strong CYP2D6 inhibitors (quinidine, paroxetine, and fluoxetine).
Based on estimations from the population pharmacokinetic analysis, CYP2D6 extensive metabolisers receiving both CYP3A4 and CYP2D6 inhibitors or CYP2D6 poor metabolisers receiving strong CYP3A4 inhibitors are expected to have approximately 4-fold to 5-fold increase in brexpiprazole concentrations and dose adjustment to a quarter of the dose is recommended for these subjects (see Dosage & Administration).
Potential for brexpiprazole to affect other medicinal products: Based on results of in vitro studies, brexpiprazole is unlikely to cause clinically important pharmacokinetic interactions with medicinal products metabolised by cytochrome P450 enzymes. Brexpiprazole does not affect absorption of medicinal products that are substrates of Breast Cancer Resistance Protein transporter (BCRP) and P-glycoprotein (P-gp) transporter.
If brexpiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance, caution should be used.
If brexpiprazole is administered concomitantly with medicinal products known to increase creatine phosphokinase (CPK) the possible additive effect with CPK increase induced by brexpiprazole should be considered.
Pharmacodynamic interactions: No information on pharmacodynamic interactions of brexpiprazole is available at present. Caution should be exercised when prescribing with other medicinal products. Given the primary Central Nervous System (CNS) effects of brexpiprazole, caution should be used when brexpiprazole is taken in combination with alcohol or other CNS medicinal products with overlapping adverse reactions such as sedation (see Adverse Reactions).

Incompatibilities: Not applicable.
Special precautions for disposal and other handling: This medicinal product may pose a risk to the environment (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Shelf life: 3 years.
Special precautions for storage: Store below 30℃ in the original container to protect from light.

Antipsychotics

N05AX16 - brexpiprazole ; Belongs to the class of other antipsychotics.

S